| pubmed-article:8697390 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8697390 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8697390 | lifeskim:mentions | umls-concept:C0034833 | lld:lifeskim |
| pubmed-article:8697390 | lifeskim:mentions | umls-concept:C1153706 | lld:lifeskim |
| pubmed-article:8697390 | lifeskim:mentions | umls-concept:C0015980 | lld:lifeskim |
| pubmed-article:8697390 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:8697390 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8697390 | pubmed:dateCreated | 1996-9-5 | lld:pubmed |
| pubmed-article:8697390 | pubmed:abstractText | The induction of estrogen and progesterone receptors (ER and PGR) has been reported in breast and endometrial cancer cells exposed to human fibroblast interferon-beta (hIFN-beta). Clinical verification of this finding might provide the rationale for new therapeutic approaches. This study was designed to evaluate whether clinical treatment with high doses of hIFN-beta induced ER and PGR in patients with endometrial adenocarcinoma. | lld:pubmed |
| pubmed-article:8697390 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8697390 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8697390 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8697390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8697390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8697390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8697390 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8697390 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8697390 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:8697390 | pubmed:author | pubmed-author:MangioniCC | lld:pubmed |
| pubmed-article:8697390 | pubmed:author | pubmed-author:D'IncalciMM | lld:pubmed |
| pubmed-article:8697390 | pubmed:author | pubmed-author:LosaGG | lld:pubmed |
| pubmed-article:8697390 | pubmed:author | pubmed-author:CodegoniA MAM | lld:pubmed |
| pubmed-article:8697390 | pubmed:author | pubmed-author:TavernaMM | lld:pubmed |
| pubmed-article:8697390 | pubmed:author | pubmed-author:LandoniFF | lld:pubmed |
| pubmed-article:8697390 | pubmed:author | pubmed-author:LucchiniVV | lld:pubmed |
| pubmed-article:8697390 | pubmed:author | pubmed-author:LomonicoSS | lld:pubmed |
| pubmed-article:8697390 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8697390 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:8697390 | pubmed:volume | 78 | lld:pubmed |
| pubmed-article:8697390 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8697390 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8697390 | pubmed:pagination | 448-53 | lld:pubmed |
| pubmed-article:8697390 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8697390 | pubmed:meshHeading | pubmed-meshheading:8697390-... | lld:pubmed |
| pubmed-article:8697390 | pubmed:meshHeading | pubmed-meshheading:8697390-... | lld:pubmed |
| pubmed-article:8697390 | pubmed:meshHeading | pubmed-meshheading:8697390-... | lld:pubmed |
| pubmed-article:8697390 | pubmed:meshHeading | pubmed-meshheading:8697390-... | lld:pubmed |
| pubmed-article:8697390 | pubmed:meshHeading | pubmed-meshheading:8697390-... | lld:pubmed |
| pubmed-article:8697390 | pubmed:meshHeading | pubmed-meshheading:8697390-... | lld:pubmed |
| pubmed-article:8697390 | pubmed:meshHeading | pubmed-meshheading:8697390-... | lld:pubmed |
| pubmed-article:8697390 | pubmed:meshHeading | pubmed-meshheading:8697390-... | lld:pubmed |
| pubmed-article:8697390 | pubmed:meshHeading | pubmed-meshheading:8697390-... | lld:pubmed |
| pubmed-article:8697390 | pubmed:meshHeading | pubmed-meshheading:8697390-... | lld:pubmed |
| pubmed-article:8697390 | pubmed:meshHeading | pubmed-meshheading:8697390-... | lld:pubmed |
| pubmed-article:8697390 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8697390 | pubmed:articleTitle | Interferon-beta can induce progesterone receptors in human endometrial adenocarcinoma. | lld:pubmed |
| pubmed-article:8697390 | pubmed:affiliation | Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy. | lld:pubmed |
| pubmed-article:8697390 | pubmed:publicationType | Journal Article | lld:pubmed |
